P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat

• Published in: Journal of the neurological sciences 1998-11, Vol.161 (1), p.16-22
• Main Authors: Goussev, Anton V, Zhang, Zhenggang, Anderson, Donald C, Chopp, Michael
• Format: Article
• Language: English
• Subjects: Animals; Anti-P-selectin antibody; Antibodies, Monoclonal - pharmacology; Arterial Occlusive Diseases - complications; Biological and medical sciences; Brain - enzymology; Brain - pathology; Cerebral Arteries - physiopathology; Cerebral Hemorrhage - etiology; Cerebral Hemorrhage - pathology; Cerebral Hemorrhage - prevention & control; Cerebral Infarction - etiology; Cerebral Infarction - pathology; Hemorrhage; Immunohistochemistry; Lesion volume; Male; Medical sciences; Middle cerebral artery occlusion; Neuropharmacology; Neuroprotective agent; P-selectin; P-Selectin - immunology; Peroxidase - metabolism; Pharmacology. Drug treatments; Rat; Rats; Rats, Wistar
• ISSN: 0022-510X; 1878-5883
• DOI: 10.1016/S0022-510X(98)00262-7

We investigated the effect of an anti-P-selectin antibody (RMP-1) on ischemic cell damage and hemorrhage after transient middle cerebral artery occlusion (MCAo) in the rat. Animals were divided into four groups: (1) antibody (Ab) 1 group ( n=14) RMP-1 (2 mg/kg) was administered to rats 1 h prior to induction of 2 h of MCA occlusion; (2) control-vehicle group Ab2 ( n=12) rats were subjected to the same experimental protocol, except that an isotype-matched control antibody was administered; (3) Ab1 group ( n=10) rats were subjected to 2 h of MCA occlusion and RMP-1 (2 mg/kg) was administered upon reperfusion; (4) control-vehicle group Ab2 ( n=10) rats were subjected to the same experimental protocol, except that an isotype-matched control antibody was administered. Animals were sacrificed 48 h after onset of the MCAo for histological evaluation of infarction and hemorrhage, and to quantify number of neutrophils. The lesion volume was significantly smaller only in pretreated rats (RMP-1 group, 18.7±3.1%) compared to the vehicle-treated (31.6±2.6%) group ( P